Ketamine in the treatment of bipolar depression
DOI:
https://doi.org/10.34119/bjhrv9n1-120Keywords:
ketamine, bipolar disorder, depression, efficacyAbstract
Bipolar depression is the most prevalent state throughout the life of the bipolar patient, even so, few studies have focused on the treatment of depression in this population. Between the available medications approved for treatment of bipolar depression, ketamine is an option that must be considered. The purpose of this paper was to review the scientific evidence on the efficacy of using ketamine to treat bipolar depression either as an adjuvant or as monotherapy. This review used data collected from clinical trials published on PUBMED between 2010 and 2021. In total, six studies were found. The results show that ketamine appears to be an alternative treatment for bipolar depression if medications considered as first and second line are not effective, although future studies are necessary.
References
BALDESSARINI, R. J. et al. Suicidal risk factors in major affective disorders. The British Journal of Psychiatry, Cambridge, v. 215, n. 4, p. 621–626, 2019.
DEAN, O. M. et al. An update on adjunctive treatment options for bipolar disorder. Bipolar Disorders, Hoboken, v. 20, n. 2, p. 87–96, 2018.
DIAZGRANADOS, N. et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry, Chicago, v. 67, n. 8, p. 793–802, 2010.
DOMINO, E. F. Taming the ketamine tiger. Anesthesiology, Philadelphia, v. 113, n. 3, p. 678–684, 2010.
FEIFEL, D.; MALCOLM, B.; BOGGIE, D.; LEE, K. Low-dose ketamine for treatment-resistant depression in an academic clinical practice setting. Journal of Affective Disorders, Amsterdam, v. 221, p. 283–288, 2017.
GOI, P. D. et al. Pharmacological treatment and staging in bipolar disorder: evidence from clinical practice. Revista Brasileira de Psiquiatria, São Paulo, v. 37, n. 2, p. 121–125, 2015.
KAMALI, M. et al. Bipolar depression and suicidal ideation: moderators and mediators of a complex relationship. Journal of Affective Disorders, Amsterdam, v. 259, p. 164–172, 2019.
KIM, J. et al. Esketamine for treatment-resistant depression — first FDA-approved antidepressant in a new class. The New England Journal of Medicine, Boston, v. 381, n. 1, p. 1–4, 2019.
LACERDA, A. L. T. Esketamine/ketamine for treatment-resistant depression. Revista Brasileira de Psiquiatria, São Paulo, v. 42, n. 6, p. 579–580, 2020.
LI, L.; VLISIDES, P. E. Ketamine: 50 years of modulating the mind. Frontiers in Human Neuroscience, Lausanne, v. 10, p. 1–15, 2016.
MCINTYRE, R. S.; CALABRESE, J. R. Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. Current Medical Research and Opinion, London, v. 35, n. 11, p. 1993–2005, 2019.
MEMON, R. I. et al. Effectiveness and safety of ketamine for unipolar depression: a systematic review. Journal of Clinical Psychopharmacology, Philadelphia, v. 40, n. 4, p. 1147–1192, 2020.
MOLERO, P. et al. Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. CNS Drugs, Auckland, v. 32, n. 5, p. 411–420, 2018.
NUGENT, A. C. et al. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disorders, Hoboken, v. 16, n. 2, p. 119–128, 2014.
PALLASKORPI, S. et al. Predominant polarity in bipolar I and II disorders: a five-year follow-up study. Journal of Affective Disorders, Amsterdam, v. 246, p. 806–813, 2019.
PLANS, L. et al. Association between completed suicide and bipolar disorder: a systematic review of the literature. Journal of Affective Disorders, Amsterdam, v. 242, p. 111–122, 2019.
POST, R. M. et al. Differential clinical characteristics, medication usage, and treatment response of bipolar disorder in the US versus the Netherlands and Germany. International Clinical Psychopharmacology, London, v. 26, n. 2, p. 96–106, 2011.
ROPPER, A. H.; SAMUELS, M. A. Bipolar disorder. The New England Journal of Medicine, Boston, v. 383, p. 58–66, 2020.
ROSENBLAT, J. D. et al. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. Bipolar Disorders, Hoboken, v. 18, n. 2, p. 89–101, 2016.
RYBAKOWSKI, J. K.; PERMODA-OSIP, A.; BARTKOWSKA-SNIATKOWSKA, A. Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression. Bipolar Disorders, Hoboken, v. 21, n. 2, p. 99–103, 2017.
RYBAKOWSKI, J. K. et al. Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Human Psychopharmacology, Hoboken, v. 28, p. 87–90, 2013.
SCHAFFER, A. et al. International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disorders, Hoboken, v. 17, n. 1, p. 1–16, 2015.
TONDO, L.; VÁZQUEZ, G. H.; BALDESSARINI, R. J. Suicidal behavior associated with mixed features in major mood disorders. Psychiatric Clinics of North America, Philadelphia, v. 43, n. 1, p. 83–93, 2020.
TONDO, L.; VÁZQUEZ, G. H.; BALDESSARINI, R. J. Prevention of suicidal behavior in bipolar disorder. Bipolar Disorders, Hoboken, v. 23, n. 1, p. 14–23, 2021.
VIGO, D.; THORNICROFT, G.; ATUN, R. Estimating the true global burden of mental illness. The Lancet Psychiatry, London, v. 3, n. 2, p. 171–178, 2016.
YATHAM, L. N. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, Hoboken, v. 20, n. 2, p. 97–170, 2018.
ZARATE JR., C. A. Ketamine: a new chapter in antidepressant development. Revista Brasileira de Psiquiatria, São Paulo, v. 42, n. 6, p. 581–582, 2020.
ZHANG, G. et al. Repeated ketamine administration redeems the time lag for citalopram’s antidepressant-like effects. European Psychiatry, Cambridge, v. 30, n. 4, p. 504–510, 2015.
ZHOU, Y. et al. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. Journal of Psychopharmacology, London, v. 32, n. 10, p. 1118–1126, 2018.
